Detonate:
Here is a post from Craig Hall when they both were with DNAP. What is the relationship between Craig Hall and Tony Frudakis? Also, how will his background in molecular biology help SUNV?
EvenPar
GenoMed, Inc. Adds Tony Frudakis, Ph.D to Scientific Advisory Board
December 7, 2001--GenoMed Inc.--("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri based medical genomics biotechnology company, announced today that Tony Frudakis, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Frudakis is the Chief Executive and Scientific Officer of DNAPrint Genomics, Inc., (NASDAQ OTC Bulletin Board: DNAP), a Sarasota, Florida based genomics company. Dr. Frudakis was recently honored as the Most Influential Scientist in the SNP and Genotyping sector by Genome Technology Magazine.
Dr. Tony Frudakis is a Phi Beta Kappa, Magna Cumme Laude graduate of the University of California. He received his doctorate degree in molecular and cell biology from the University of California, Berkeley, and has 14 years of experience as a molecular biologist. Dr. Frudakis' career has resulted in a patent portfolio of over 350 unique genes and 2 products.
Jerry White, GenoMed's President & Chief Executive Officer, stated that, "It is a great honor to welcome Dr. Frudakis to our Scientific Advisory Board. His experience and expertise within the area of medical genetics is a tremendous asset to our Scientific Advisory Board and we are very fortunate to have him as a member of our advisory board."
"Not only does population genetics need more horsepower, but it needs the type of horsepower that GenoMed will provide. Although GenoMed's research will differ from that of DNAPrint, it is worthy research that addresses a real need in the field. I am pleased to have a chance to interact with GenoMed in a scientifically meaningful way", said Tony Frudakis, Ph.D.
About GenoMed
GenoMed was founded with the sole purpose of translating knowledge of disease genes into better patient outcomes as rapidly and as safely as possible. The Company's business model specifically links improved patient outcomes to Company revenues through clinical treatment and genetic diagnoses of diseases.
For additional information please visit www.genomedics.com and/or contact Craig Hall @ (941) 366-6677 or email at chall@floridafunds.com.